These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36928494)

  • 1. A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Podolanczuk AJ; Cottin V
    Adv Ther; 2023 May; 40(5):2038-2050. PubMed ID: 36928494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
    Cottin V; Martinez FJ; Jenkins RG; Belperio JA; Kitamura H; Molina-Molina M; Tschoepe I; Coeck C; Lievens D; Costabel U
    Respir Res; 2022 Apr; 23(1):85. PubMed ID: 35392908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Cottin V
    Expert Opin Drug Saf; 2017 Jul; 16(7):857-865. PubMed ID: 28571476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials.
    Hoffmann-Vold AM; Volkmann ER; Allanore Y; Assassi S; de Vries-Bouwstra JK; Smith V; Tschoepe I; Loaiza L; Kanakapura M; Distler O
    Lancet Rheumatol; 2022 Oct; 4(10):e679-e687. PubMed ID: 38265966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Sarr C; Freiwald M
    BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil.
    Pereira CAC; Baddini-Martinez JA; Baldi BG; Jezler SFO; Rubin AS; Alves RLR; Zonzin GA; Quaresma M; Trampisch M; Rabahi MF
    J Bras Pneumol; 2019 Sep; 45(5):e20180414. PubMed ID: 31531619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
    Lancaster L; Crestani B; Hernandez P; Inoue Y; Wachtlin D; Loaiza L; Quaresma M; Stowasser S; Richeldi L
    BMJ Open Respir Res; 2019; 6(1):e000397. PubMed ID: 31179001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
    Corte T; Bonella F; Crestani B; Demedts MG; Richeldi L; Coeck C; Pelling K; Quaresma M; Lasky JA
    Respir Res; 2015 Sep; 16():116. PubMed ID: 26400368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
    Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
    Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
    Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
    Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases.
    Ono M; Kobayashi S; Masakazu H; Ishida M; Sato H; Okutomo K; Shirai Y; Takahashi K; Yamada M; Fujino N; Yamanda S; Yanai M
    Medicine (Baltimore); 2024 Jul; 103(28):e38920. PubMed ID: 38996147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.
    Mira-Avendano I; Kaye M
    Ther Adv Respir Dis; 2024; 18():17534666241266343. PubMed ID: 39113425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
    Rodríguez-Portal JA
    Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study.
    Komatsu M; Yamamoto H; Ichiyama T; Kawakami S; Uehara T; Yoshikawa Y; Kitaguchi Y; Ushiki A; Yasuo M; Hanaoka M
    PLoS One; 2022; 17(2):e0262795. PubMed ID: 35113907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
    Glaspole I; Bonella F; Bargagli E; Glassberg MK; Caro F; Stansen W; Quaresma M; Orsatti L; Bendstrup E
    Respir Res; 2021 Apr; 22(1):125. PubMed ID: 33902584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
    Seibold JR; Maher TM; Highland KB; Assassi S; Azuma A; Hummers LK; Costabel U; von Wangenheim U; Kohlbrenner V; Gahlemann M; Alves M; Distler O;
    Ann Rheum Dis; 2020 Nov; 79(11):1478-1484. PubMed ID: 32759258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.